Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.83 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 10/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4913311 | 0.93 | TP53 (0.71) | TP53GAAMAPTALDH1A1HPGD | |
| SCHEMBL4907867 | 0.91 | TP53 (1.00) | TP53GAAMAPTALDH1A1HPGD | |
| SCHEMBL4597022 | 0.91 | TP53 (1.00) | TP53GAAMAPTALDH1A1HPGD | |
| SCHEMBL4914127 | 0.90 | TP53 (0.98) | TP53GAAMAPTALDH1A1HPGD | |
| SCHEMBL4504134 | 0.87 | GAA (0.73) | TP53GAAMAPTALDH1A1HPGD | |
| SCHEMBL4911814 | 0.85 | GAA (0.71) | TP53GAAMAPTALDH1A1HPGD | |
| SCHEMBL4229143 | 0.85 | TP53 (0.66) | TP53GAAMAPTALDH1A1HPGD | |
| SCHEMBL4911281 | 0.85 | MAPT (0.66) | TP53GAAMAPTALDH1A1HPGD | |
| SCHEMBL4910091 | 0.85 | MAPT (0.74) | TP53GAAMAPTALDH1A1HPGD | |
| SCHEMBL4902812 | 0.85 | TP53 (0.73) | TP53GAAMAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221185-A1 | Glyt1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders | GLAXO GROUP LIMITED (GB) | 2008-09-11 | — | — | US | claimed |
| US-20080221185-A1 | Glyt1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders | GLAXO GROUP LIMITED (GB) | 2008-09-11 | — | — | US | disclosed |
| US-20080221185-A1 | Glyt1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders | GLAXO GROUP LIMITED (GB) | 2008-09-11 | — | — | US | disclosed |
| US-20080221185-A1 | Glyt1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders | GLAXO GROUP LIMITED (GB) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221185-A1 | Glyt1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders | SLC18A2, SLC6A3, SLC1A2 | TP53 4008/4885GAA 537/4885MAPT 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.